Cargando…

Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation

BACKGROUND AND PURPOSE: Prostate specific membrane antigen positron emission tomography imaging (PSMA-PET) has demonstrated potential for intra-prostatic lesion localization. We leveraged our existing database of co-registered PSMA-PET imaging with cross sectional digitized pathology to model dose c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Christopher W., Alfano, Ryan, Hoover, Douglas, Surry, Kathleen, D'Souza, David, Thiessen, Jonathan, Rachinsky, Irina, Butler, John, Gomez, Jose A., Gaed, Mena, Moussa, Madeleine, Chin, Joseph, Pautler, Stephen, Bauman, Glenn S., Ward, Aaron D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459608/ https://www.ncbi.nlm.nih.gov/pubmed/34589619 http://dx.doi.org/10.1016/j.phro.2021.07.001

Ejemplares similares

Short-duration dynamic [(18)F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [(18)F]DCFPyL PET/MR at 120 minutes
por: Yang, Dae-Myoung, et al.
Publicado: (2021)

Histologic tissue components provide major cues for machine learning-based prostate cancer detection and grading on prostatectomy specimens
por: Han, Wenchao, et al.
Publicado: (2020)

3D prostate histology image reconstruction: Quantifying the impact of tissue deformation and histology section location
por: Gibson, Eli, et al.
Publicado: (2013)

The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).
por: Mendez, Lucas C., et al.
Publicado: (2023)

Kinetic analysis of dominant intraprostatic lesion of prostate cancer using quantitative dynamic [(18)F]DCFPyL-PET: comparison to [(18)F]fluorocholine-PET
por: Yang, Dae-Myoung, et al.
Publicado: (2021)

Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy
por: Chapman, Christopher H, et al.
Publicado: (2018)

Dose escalation in oropharyngeal cancer: a comparison of simultaneous integrated boost and brachytherapy boost
por: Embring, Anna, et al.
Publicado: (2023)

Salvage low-dose-rate (125)I partial prostate brachytherapy after dose-escalated external beam radiotherapy
por: Chang, Lynn, et al.
Publicado: (2014)

A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
por: Correa, Rohann J. M., et al.
Publicado: (2018)

Dose differentiated high-dose-rate prostate brachytherapy: a feasibility assessment of MRI-guided dose escalation to dominant intra-prostatic lesions
por: Luminais, Christopher K., et al.
Publicado: (2022)

Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era
por: Tamihardja, Jörg, et al.
Publicado: (2022)

Individualized Dose-Escalation of HDR Prostate Brachytherapy Implant to Decrease Required External Beam Radiation Dose: A Retrospective Feasibility Study
por: Dahn, Hannah M., et al.
Publicado: (2019)

Imaging Cherenkov emission for quality assurance of high-dose-rate brachytherapy
por: Yogo, Katsunori, et al.
Publicado: (2020)

Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody
por: Yang, Yanling, et al.
Publicado: (2021)

Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9–10 clinical localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2022)

Dose escalation of a curcuminoid formulation
por: Lao, Christopher D, et al.
Publicado: (2006)

Dose escalation via brachytherapy boost for nasopharyngeal carcinoma in the era of intensity-modulated radiation therapy and combined chemotherapy
por: Chao, Hsing-Lung, et al.
Publicado: (2017)

Results of a Prospective Dose Escalation Study of Linear Accelerator–Based Virtual Brachytherapy (BOOSTER) for Prostate Cancer; Virtual HDR Brachytherapy for Prostate Cancer
por: Eade, Thomas, et al.
Publicado: (2019)

National trends in radiation dose escalation for glioblastoma
por: Wegner, Rodney E., et al.
Publicado: (2019)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

Efficacy and toxicity of image-guided intensity-modulated radiation therapy combined with dose-escalated brachytherapy for stage IIB cervical cancer
por: Wang, Weiping, et al.
Publicado: (2017)

Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy
por: Yamazaki, Hideya, et al.
Publicado: (2021)

Need of independent dose verification in brachytherapy
por: Shanta, A
Publicado: (2008)

Low dose rate prostate brachytherapy
por: Stish, Bradley J., et al.
Publicado: (2018)

An automated dose verification software for brachytherapy
por: Wang, Xianliang, et al.
Publicado: (2018)

Feasibility of Dose Escalating [(18)F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate Cancer
por: McDonald, Andrew M., et al.
Publicado: (2019)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Contralateral breast dose from partial breast brachytherapy
por: Robinson, R. Cole, et al.
Publicado: (2015)

Radiation treatment planning with embedded dose escalation
por: Hrinivich, William T., et al.
Publicado: (2019)

The role of biological dose-escalation for pancreatic cancer
por: Bruynzeel, Anna M.E., et al.
Publicado: (2019)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

Hypofractionated High-Dose Irradiation with Positron Emission Tomography Data for the Treatment of Glioblastoma Multiforme
por: Miwa, Kazuhiro, et al.
Publicado: (2014)

Preclinical dosimetry models and the prediction of clinical doses of novel positron emission tomography radiotracers
por: Garrow, Adam A., et al.
Publicado: (2020)

Interstitial brachytherapy for liver metastases and assessment of response by positron emission tomography: a case report
por: Sharma, Daya Nand, et al.
Publicado: (2010)

Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy – a meta-analysis of clinical trials
por: Viani, Gustavo A, et al.
Publicado: (2009)

Dose gradient impact on equivalent dose at 2 Gy for high dose rate interstitial brachytherapy
por: Hannoun-Levi, Jean-Michel, et al.
Publicado: (2012)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Escalation of Tau Accumulation after a Traumatic Brain Injury: Findings from Positron Emission Tomography
por: Mohamed, Abdalla Z., et al.
Publicado: (2022)

Multimodality image fusion in dose escalation studies of brain tumors
por: Rajasekar, D., et al.
Publicado: (2000)

Verification of high-dose-rate brachytherapy treatment planning dose distribution using liquid-filled ionization chamber array
por: Mohamed Yoosuf, A.B., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kvd6u4trhata8oodauhphtc824